-+ 0.00%
-+ 0.00%
-+ 0.00%
UBS: The success rate of negotiations on the national health insurance catalogue remains high and Class 1 innovative drugs reach a record high
Share
Listen to the news

The Zhitong Finance App learned that UBS released a research report saying that the National Health Insurance Administration announced the 2026 National Medical Insurance Drug Catalogue and Commercial Insurance Innovative Drug Catalogue. Of the 124 drug candidates reviewed, 107 were included in the medical insurance catalogue, and 34 were transferred due to factors such as clinical substitution and supply, bringing the total number of drugs covered by the medical insurance catalogue to 3,331, an increase of 2.4% over the previous year. The success rate of national health insurance catalogue negotiations remained high.

The bank pointed out that of the 107 newly included drugs, 51 were Class 1 innovative drugs, accounting for nearly half of the total number of new drugs, a record high; all 12 negotiated drugs in the commercial insurance innovative drug catalogue were also included. The bank believes that this year's adjustments are generally stable, industry participation is strong, and the negotiation success rate is high. However, the price reduction will not be confirmed until the two catalogues officially come into effect on January 1, 2027.

In terms of pharmaceutical companies, products such as Hanson Pharmaceuticals (03692), CSPC Pharmaceutical (01093), China Biopharmaceuticals (01177), Xiansheng Pharmaceutical (02096), and Sansheng Pharmaceutical (01530) have included or added new indications.

Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.
What's Trending